Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
GEP-NETs
Lanreotide
Neuroendocrine tumors
Octreotide
Real-world
SNDS
Somatostatin analogues
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
29
10
2021
accepted:
26
01
2022
pubmed:
23
2
2022
medline:
12
4
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
Long-acting somatostatin analogues such as lanreotide autogel (LAN) and octreotide long-acting release (OCT) are recommended as first-line treatment for patients with neuroendocrine tumors (NETs). However, only few real-world studies have compared the two medications. This retrospective, observational cohort study used a French claims database to compare patterns of use with LAN vs. OCT in patients with NETs. Data on LAN and OCT patterns of use were obtained retrospectively from the National System of Health Data (SNDS), a national French claims database. Patients 18 years of age or older who initiated treatment for NETs between 2009 and 2016, and who received at least six subsequent dispensings of first-line LAN or OCT during the first year of treatment, were included. A subgroup analysis was performed on patients with gastroenteropancreatic (GEP)-NETs. Patients receiving LAN (n = 2327) vs. OCT (n = 2090) had greater median treatment duration (31.8 months vs. 22.1 months, respectively; p < 0.0001; log-rank test) and were less likely to discontinue treatment; adjusted hazard ratio (HR) 0.74 (95% confidence interval [CI] 0.69-0.80). In year 1, a significantly lower percentage of patients receiving LAN vs. OCT switched treatments (10.4% vs. 22.2%, respectively; p < 0.0001), received an average monthly dose per trimester above recommended dose (3.0% vs. 7.3%, respectively; p < 0.0001), and used rescue medication (3.1% vs. 10.0%, respectively; p < 0.0001). Dispensing of pancreatic enzymes was significantly higher in patients receiving LAN than OCT (16.4% vs. 13.9%, respectively). In the subgroup of patients with GEP-NETs, those receiving LAN (n = 1478) vs. OCT (n = 1278) had greater treatment duration and less treatment discontinuation, switching, dosage above the recommended dose, and rescue medication use, but no significant difference in dispensing of pancreatic enzymes or time to second-line treatment. These real-world data suggest potential clinical and economic advantages of LAN over OCT in the management of patients with NETs in the French population.
Identifiants
pubmed: 35190997
doi: 10.1007/s12325-022-02060-1
pii: 10.1007/s12325-022-02060-1
pmc: PMC8989892
doi:
Substances chimiques
Peptides, Cyclic
0
Somatostatin
51110-01-1
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1754-1771Commentaires et corrections
Type : ErratumIn
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Shah MH, Goldner WS, Benson AB III, et al. Neuroendocrine and adrenal tumors, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839–68. https://doi.org/10.6004/jnccn.2021.0032 .
doi: 10.6004/jnccn.2021.0032
pubmed: 34340212
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42 (2374–2445 (Electronic)).
doi: 10.1001/jamaoncol.2017.0589
pubmed: 28448665
pmcid: 5824320
Frilling A, Akerström G, Falconi M, et al. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012;19(5):R163–85 (1479–6821 (Electronic)).
doi: 10.1530/ERC-12-0024
pubmed: 22645227
van der Zwan JM, Trama A, Otter R, et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013;49(11):2565–78 (1879–0852 (Electronic)).
doi: 10.1016/j.ejca.2013.02.029
pubmed: 23541566
Beaumont JL, Cella D, Phan AT, et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461–6 (1536–4828 (Electronic)).
doi: 10.1097/MPA.0b013e3182328045
pubmed: 22422138
Leyden JA-O, Pavlakis N, Chan D, et al. Patient-reported experience of the impact and burden of neuroendocrine tumors: oceania patient results from a large global survey. Asia Pac J Clin Oncol. 2018;14(3):256–63 (1743–7563 (Electronic)).
doi: 10.1111/ajco.12785
pubmed: 29105989
Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2017;3(1):43–53 (2378–9506 (Print)).
doi: 10.1200/JGO.2015.002980
pubmed: 28717741
Wolin EM, Leyden J, Goldstein G, et al. Patient-reported experience of diagnosis, management, and burden of neuroendocrine tumors: results from a large patient survey in the United States. Pancreas. 2017;46(5):639–47.
doi: 10.1097/MPA.0000000000000818
pubmed: 28328615
pmcid: 5404397
Fazio N, de Braud F, Delle Fave G, Oberg K. Interferon-α and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol. 2007;18:13–9.
doi: 10.1093/annonc/mdl144
pubmed: 16798833
Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85.
doi: 10.1159/000443167
pubmed: 26731013
de Mestier L, Lepage C, Baudin E, et al. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2020;52(5):473–92.
doi: 10.1016/j.dld.2020.02.011
pubmed: 32234416
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.
doi: 10.1016/j.annonc.2020.03.304
pubmed: 32272208
Hofland J, Feelders RA, Brabander T, et al. Recent developments in the diagnosis and therapy of well-differentiated neuroendocrine tumours. Neth J Med. 2018;76(3):100–108.
Vinik AI, Wolin EM, Liyanage N, et al. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (elect): a randomized, double-blind, Placebo-Controlled Trial. Endocr Pract. 2016;22(9):1068–80.
doi: 10.4158/EP151172.OR
pubmed: 27214300
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.
doi: 10.1056/NEJMoa1316158
pubmed: 25014687
emc. Somatuline Autogel 60 mg, 90 mg, 120 mg solution for injection in a prefilled syringe. https://www.medicines.org.uk/emc/product/4808/smpc . Accessed 15 Mar 2021.
Rinke A, Müller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.
doi: 10.1200/JCO.2009.22.8510
pubmed: 19704057
emc. Sandostatin LAR 10 mg, 20 mg or 30 mg powder and solvent for suspension for injection. https://www.medicines.org.uk/emc/product/1038/smpc#gref . Accessed 15 Mar 2021
ISPOR. 2020 Top 10 HEOR TRENDS. https://www.ispor.org/docs/default-source/heor-resources/2020-top-10-heor-trends_v-online_00120191219.pdf?sfvrsn=9eebcb74_0 . Accessed 19 Mar 2021.
Klink A, Feinberg B, Yu H-T, et al. Patterns of care among real-world patients with metastatic neuroendocrine tumors. Oncologist. 2019;24:1331–9.
doi: 10.1634/theoncologist.2018-0798
pubmed: 31015313
pmcid: 6795156
Cheung WY, Feuilly M, Laforty C, et al. A real-world observational study of somatostatin analogue use and costs in Canada. J Clin Oncol. 2020;38(4_suppl):608.
doi: 10.1200/JCO.2020.38.4_suppl.608
Scailteux L-M, Droitcourt C, Balusson F, et al. French administrative health care database (SNDS): the value of its enrichment. Therapies. 2019;74(2):215–23.
doi: 10.1016/j.therap.2018.09.072
Fagnani F, Feuilly M, de Zélicourt M et al. Lanreotide autogel and octreotide LAR treatment patterns: results from a nationwide French retrospective study. ENETS 2020.
Somatuline L.P. 30 mg extended-release suspension for injection (IM) powder and solvent—Summary of product characteristics. Ministere des Solidarites et de la Sante; 2021.
Lesén E, Granfeldt D, Berthon A, et al. Treatment patterns and survival among patients with metastatic gastroenteropancreatic neuroendocrine tumours in Sweden—a population-based register-linkage and medical chart review study. J Cancer. 2019;10(27):6876–87.
doi: 10.7150/jca.32381
pubmed: 31839822
pmcid: 6909946
Benson AB III, Broder MS, Cai B, et al. Real-world treatment patterns of gastrointestinal neuroendocrine tumors: a claims database analysis. World J Gastroenterol. 2017;23(33):6128–36.
doi: 10.3748/wjg.v23.i33.6128
pubmed: 28970728
Chen C-C, Parikh K, Abouzaid S, et al. Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib. J Manag Care Spec Pharm. 2017;23(2):236–46.
pubmed: 28125372
Huynh L, Cai B, Cheng M, et al. Analysis of real-world treatment patterns, healthcare resource utilization, and costs between octreotide and lanreotide among patients with neuroendocrine tumors. Pancreas. 2019;48(9):1126–35.
doi: 10.1097/MPA.0000000000001403
pubmed: 31593022
Ipsen. Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. IPSEN. https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2014/12/06185010/12-2014-corporate-PR-Approval-Somatuline-US-FINAL.pdf . Accessed 19 Mar 2021.
FDA. Highlights of prescribing information: somatuline depot (lanreotide) injection, for subcutaneous use. FDA; 2018.
Somatuline LP. 120 mg, solution injectable a liberation prolongee en seringue preremplie. Ministere Des Solidarites et de la Sante; 2021.
Somatuline LP. 90 mg, solution injectable a liberation prolongee en seringue preremplie. Ministeres Des Solidarites et de la Sante; 2021.
Somatuline LP. 60 mg, pre-filled syringe solution for injection. Ministere Des Solidarites et de la Sante; 2021.
Novartis Pharmaceuticals Corporation. Highlights of prescribing information: sandostatin LAR depot (octreotide acetate) for injectable suspension, for gluteal intramuscular use. East Hanover: Novartis Pharmaceuticals Corporation; 2021.
Sandostatine LP. 30 mg, poudre et solvant pour suspension injectable. Ministere des Solidarites et de la Sante; 2021.
Sandostatine LP. 10 mg, poudre et solvant pour suspension injectable. Ministere des Solidarites et de la Sante; 2021.
Sandostatin LP. 20 mg powder and solvent for suspension for injection. Ministere des Solidarites et de la Sante; 2021.
Lamarca A, McCallum L, Nuttall C, et al. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Exp Rev Gastroenterol Hepatol. 2018;12(7):723–31 (1747–4132 (Electronic)).
doi: 10.1080/17474124.2018.1489232
Trang T, Chan J, Graham DY. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century. World J Gastroenterol. 2014;20(33):11467–85.
doi: 10.3748/wjg.v20.i33.11467
pubmed: 25206255
pmcid: 4155341